Urogen Pharma’s (URGN) “Buy” Rating Reaffirmed at HC Wainwright

Urogen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report released on Wednesday, MarketBeat Ratings reports. They presently have a $45.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 69.56% from the stock’s previous close.

Several other equities analysts also recently issued reports on the stock. Jefferies Financial Group upgraded shares of Urogen Pharma to a “strong-buy” rating in a research note on Friday, April 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Monday, April 20th. D. Boral Capital reissued a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a report on Tuesday, March 31st. LADENBURG THALM/SH SH began coverage on Urogen Pharma in a research report on Monday, May 11th. They issued a “buy” rating and a $43.00 target price for the company. Finally, Oppenheimer restated an “outperform” rating on shares of Urogen Pharma in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $36.67.

Urogen Pharma Trading Down 1.8%

URGN stock opened at $26.54 on Wednesday. Urogen Pharma has a twelve month low of $4.71 and a twelve month high of $32.37. The company’s 50 day moving average is $23.91 and its two-hundred day moving average is $22.65. The stock has a market cap of $1.29 billion, a P/E ratio of -9.65 and a beta of 1.59.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.01. The company had revenue of $50.96 million during the quarter, compared to analyst estimates of $44.83 million. On average, equities research analysts predict that Urogen Pharma will post -0.98 earnings per share for the current year.

Institutional Investors Weigh In On Urogen Pharma

Several hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Urogen Pharma by 27.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after buying an additional 486 shares during the last quarter. State of Wyoming purchased a new position in shares of Urogen Pharma in the 3rd quarter valued at approximately $66,000. Russell Investments Group Ltd. increased its holdings in shares of Urogen Pharma by 1,594.4% in the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after purchasing an additional 3,125 shares during the period. Osaic Holdings Inc. increased its holdings in shares of Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after purchasing an additional 3,070 shares during the period. Finally, Strs Ohio purchased a new stake in shares of Urogen Pharma during the third quarter worth approximately $76,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.